About Timber Pharmaceuticals
Timber Pharmaceuticals was founded in 2019 to develop treatments for unmet needs in medical dermatology. We have a particular focus on rare diseases or conditions of the skin for which there are no current treatments. Rare skin diseases are among the most neglected therapeutic areas in the pharmaceutical industry.
We are targeting multiple indications in rare/orphan dermatology with no approved treatments. Our investigational therapies have proven mechanisms-of-action backed by decades of clinical experience and well-established CMC (chemistry, manufacturing and control) and safety profiles.
Timber was initially formed around the collaboration of three companies with demonstrated experience in all phases of drug development and clinical research. Our team includes world class advisors and a strong leadership team with a proven track record of success in advancing therapies to treat both rare diseases and dermatologic diseases and conditions. On January 23, 2024, LEO Pharma announced that it had finalized its acquisition of TMB-001 as well as other strategic assets of Timber Pharmaceuticals.